Purpose The purpose of this study is to establish the role of Achieve Mapping Catheter in cryoablation for paroxysmal atrial fibrillation (PAF) in a randomized trial. Methods A total of 102 patients undergoing their first ablation for PAF were randomized at 2:1 to an Achieve-or Lassoguided procedure. Study patients were systematically followed up for 12 months with Holter monitoring. Primary study endpoint was acute procedure success. Secondary endpoint was clinical outcomes assessed by AF free at 6 and 12 months after the procedure. Results Of 102 participants, 99 % of acute procedure success was achieved. Significantly shorter procedure duration with the Achieve-guided group than with the Lasso-guided group (118 ± 18 vs. 129 ± 21 min, p < 0.05) was observed as was the duration of fluoroscopy (17 ± 5 vs. 20 ± 7 min, p < 0.05) by subgroup analysis focused on procedures performed by experienced operators. In the whole study patients, procedure and fluoroscopic durations were similar in the Achieve-(n = 68) and Lasso-guided groups (n = 34). Transient phrenic nerve weakening was equally prevalent with the Achieve and Lasso. No association was found between clinical outcomes and the mapping catheter used. The use of second-generation cryoballoon (n = 68) reduced procedure time significantly compared to the first-generation balloon (n = 34); more patients were free of AF in the former than the latter group during follow-up. Conclusions The use of the Achieve Mapping Catheter can reduce procedure and fluoroscopic durations compared with Lasso catheters in cryoablation for PAF after operators gained sufficient experience. The type of mapping catheter used does not affect procedure efficiency and safety by models of cryoballoon.
Introduction
Pulmonary vein isolation (PVI) is the most important component of catheter ablation for patients with paroxysmal atrial fibrillation (PAF) and constitutes a sufficient therapy in the majority of cases [1] . PVI can be accomplished using a cryoballoon ablation catheter more efficiently than by Bpoint-by-point^ablation using radiofrequency energy [2, 3] .
The Achieve Mapping Catheter® (Medtronic) is an octapolar circular mapping catheter that passes through the central lumen of the cryoballoon, permitting PV electrogram recording during cryotherapy delivery [4] , even in the presence of substantial structural abnormality [5] . Before the Achieve catheter became available, PV electrograms were recorded using a traditional BLasso-stylem ultipolar circular mapping catheter either by delivering it through the same transseptal sheath as the cryoballoon before and after cryotherapy or by delivering it through a separate transseptal puncture, in which case it can be used during cryotherapy in any vein other than the one being cryoablated at that time [6] . The Achieve Mapping Catheter was designed with the expectation of improved procedural efficacy and safety compared to the conventional 'Lasso-style' mapping catheter. Although a few early studies reported its clinical value, randomized trials focusing on the Achieve Mapping Catheters in cryoballoon ablation for AF are sparse.
The current study aimed to assess the efficacy, efficiency, and safety of the Achieve Mapping Catheter compared to the Lasso-style circular mapping catheter in a randomized study design in PVI procedure for patients with PAF. During enrolment for this trial, the original Arctic Front (AFO) was superseded by the Arctic Front Advance [7] [8] [9] [10] ; we managed this transition in a stratified manner to allow comparison between the devices.
Methods

Study population
We recruited patients with PAF [11] who underwent their first AF ablation into this study at St. George's Hospital (London, UK) between November 2011 and October 2013. PAF patients who were suffering from symptomatic PAF, were refractory to medical therapy, and aged greater than 18 years old were eligible for recruitment. Patients who had prior left atrial ablation or any contraindication to left atrial ablation were excluded. Study patients underwent transesophageal echocardiography within 1 week before the procedure; no other form of pre-procedure cardiac imaging was utilized.
Study participants were randomly assigned to two arms, cryoballoon ablation with either the usage of an Achieve Mapping Catheter or a Lasso-guided technique. Treatment was randomized in a 2:1 (Achieve to Lasso ratio) manner by using a computer-generated randomization number. This unequal allocation was chosen because all of the operators were experienced in the Lasso-guided technique before the study began but had little or no experience with the Achieve Mapping Catheter. We assigned more cases to the Achieve-guided group so that significant experience in the Achieve-guided technique could be accumulated by each operator, allowing us to perform subgroup analysis to correct for this obvious confounding factor. The assignment was revealed to the operator in the EP laboratory at the beginning of the procedure.
This study complies with the Declaration of Helsinki; the research protocol was approved by the Research Ethical Committee of London, and all participants had given written informed consent before the procedure.
Ablation procedure
A standard PVI procedure was performed on all cases [12] . The investigators used two or three points of venous access, one of which was used to place of a diagnostic catheter in the coronary sinus. A single transseptal puncture was performed, and a venogram of each PV was obtained. The selection of cryoballoon size (23 vs. 28 mm) was based on PV size using venography. Before each delivery of cryotherapy, the quality of occlusion was quantified (details are in the caption of Fig. 1) by venography (Fig. 1) and by measuring the pressure recorded through the central lumen of the balloon catheter. When necessary, a second balloon of a different size may be used, but this practice was discouraged throughout the study. General anesthesia was available to patients who requested it.
In patients assigned to the Lasso group, the PVs were mapped with a Lasso circular mapping catheter before and after cryotherapy, using a single transseptal puncture and delivering the mapping catheter through the dedicated cryoballoon sheath (FlexCath Steerable Sheath). If the Achieve was used, the PV electrograms were monitored continuously during the cryoballoon freeze in each PV. The time to isolation (TTI) was recorded whenever the effect of acute isolation was visible during cryotherapy. TTI was defined from the onset of ablation to electrogram elimination or dissociation of PV potentials and calculated using the clock time displayed on the Bard system. After all PVs were treated, each PV was again mapped to confirm and record the persistence of isolation that was achieved at 15 min post ablation.
In all procedures, at least two cryoballoon ablation deliveries were applied to each of the PV ostia. The delivery of cryotherapy could be aborted at the discretion of the operator if either (1) the PV was not isolated within 100 s; (2) if the temperature failed to descend to −40°C; or (3) any warning signs of phrenic nerve injury were observed. All satisfactory freezes lasted for 240-300 s. The standard freezing cycle duration of 300 s was applied in all cases using the AFO and the first 27 cases performed using the Arctic Front Advance (AFA); thereafter, the freeze duration was reduced to 240 s in the AFA group to avoid potential freezing complications after more information regarding the AFA became available.
The AFA catheter became available during our study enrollment, we introduced it in a stratified manner designed to avoid an order effect and compared it objectively to the older model of cryoballoon with a balance between AFA and AFO in each of the randomized assignment groups.
After all of the PVs were treated by this protocol, if necessary, any remaining points of electrical communication were ablated with a large curve Freezor Max ablation catheter delivered via the existing transseptal puncture or a second transseptal puncture at the discretion of the operator.
During cryotherapy of the right side PVs, the diagnostic catheter was re-sited from the coronary sinus to the superior vena cava for continuous pacing of the phrenic nerve (PN). PN capture was constantly monitored by palpation of the thoracic cage at the level of the xiphisternum. If weakening or loss of diaphragmatic movement in response to the pacing stimuli was noted, the freezing delivery was immediately stopped, and the balloon was quickly deflated by pressing the stop button on the Cryo Console twice.
The procedural endpoint was defined as persistent PVI, which was verified by circular mapping catheter recordings at least 15 min after the last application of cryotherapy to that vein. Data were collected throughout the study by a dedicated researcher instructed by the operator during the procedure, and the data were reviewed by the operator at the end of each case.
Procedural complications
Complications were defined prospectively as unintended consequences of the procedure that led to patient suffering or to prolongation of the patient's hospital admission. Major adverse events were defined as complications that constituted a threat to life, involved blood loss requiring transfusion, prolonged the hospital admission to more than 1 week, or led to adverse symptoms or functional limitation extending for longer than 3 months.
Any alteration of the phrenic nerve function was recorded. Transient phrenic weakening (tPNW) was defined as a weakening or loss of diaphragmatic response to PN during cryotherapy with a full return to normal strength before the end of the procedure; tPNW did not fulfill our prospective definition of a complication and was considered as a warning sign of averted events. Temporary phrenic nerve injury (tPNI) was defined as a weakening of phrenic response to electrical stimulation that persisted beyond the end of the procedure but was followed by a full return to normal function by the following day; because this prompted a pre-discharge chest radiograph and therefore delayed discharge by several hours, it was considered as a complication. Phrenic nerve palsy (PNP) was diagnosed if there was a loss of phrenic response persisting to the end the procedure with elevation of the hemidiaphragm chest radiography on the following or subsequent days.
Study follow-up
All AF ablation patients were scheduled to be discharged from hospital the day after the procedure. Every participant was interviewed at their bedside the morning after ablation, and a telephone interview was conducted at 2 months after the procedure by a dedicated researcher. Further follow-ups were scheduled at 3, 6, and 12 months post ablation with attendance The degree of occlusion of the pulmonary vein obtained for each cryothermal therapy delivery was quantified on a scale of 1-5 using the following criteria. Grade 5 occlusion described an appearance in which contrast injected through the central lumen of the balloon catheter was seen to remain in the peripheral pulmonary veins without accumulation close to the balloon. Grade 4 occlusion was associated with a distribution of contrast density that was homogeneous from the peripheral veins to the surface of the balloon or was more concentrated at the balloon than in the peripheral veins but showed no visible leakage of contrast to the left atrium. Grade 3 occlusion was used when there was a visible point or points of leakage of contrast from the vein to the atrium, but the overall flow was so slow that the vein remained densely opacified by contrast for >5 s after injection; the contrast leak had a thread-or hair-like appearance. Grade 2 was used when a larger leak was larger but vein opacification still occurred. Grade 1 was used when the leak was so severe that no opacification of the vein occurred, just a stream of contrast from the injection point past the balloon to the atrium at an arrhythmia clinic, including a 48-h Holter monitor at each follow-up point.
AF recurrence was defined as any episode of AF/AT >30 s, either symptomatic or asymptomatic, documented on a Holter ECG and/or 12-lead resting ECG [13] or other long-term ECG recording devices [9, 14] during follow-up. A 3-month blanking period was applied to calculations of freedom from AF [9] .
Statistical analysis
Continuous variables are presented as mean ± SD, where appropriate. Categorical variables are expressed as numbers and percentage of patients. Comparison of numeric values of all measurements was performed using the Mann-Whitney U test or Student's two-tail t test depending on the data distribution, and comparison of categorical variables was tested by chisquare or Fisher exact test, as appropriate. All statistical analyses were performed using the SPSS software (SPSS v20, IL, USA) or Microsoft Excel (2010). A p value <0.05 was considered statistically significant.
Power calculations
A prospective power calculation was performed based on the standard deviation of the procedure duration and fluoroscopy duration for 10 consecutive Arctic Front procedures performed while the study was being designed. With a sample size of 102 and a 2:1 randomization, we calculated a 90 % probability of being able to detect a 14-min difference between the groups in the procedure duration at a 5 % significance level.
Results
Patients
A total of 102 participants (age 62 ± 12 years, range 22.6-83.2 years, 52 male) were randomized and treated (Fig. 2) . Sixty-eight patients were randomized to the Achieve group and 34 to the Lasso group. There was no significant difference in clinical characteristic between the study groups ( Table 1) . Twenty patients in the Achieve group and 9 in the Lasso group (29 vs. 26 %, p = ns) underwent their ablation procedure under general anesthesia. All study patients completed their 6-month follow-up. Two participants died of causes unrelated to ablation procedure or the arrhythmia before 12-month follow-up. Another two participants withdrew/were lost from/to the follow-up between 6 and 12 months post ablation. 
Comparison of the mapping techniques
The mean procedure time, measured from skin puncture to the removal of the last venous sheath, was similar in the Achieve and the Lasso groups (126 ± 20 vs. 129 ± 21 min, p = ns). No significant difference was observed in the fluoroscopic time between the Achieve and Lasso groups (21 ± 13 vs. 20 ± 7 min, p = ns) in the whole study population.
Because the study began soon after the introduction of the Achieve Mapping Catheter, all the operators were all inexperienced in its use at the start of the study but were experienced in the use of the cryoballoon directed by Lasso mapping and guide wire delivery. We therefore reanalyzed the data excluding operators who were still in the first 10 cases of their experience with the Achieve Mapping Catheter. In the subgroup (n = 51) who underwent an Achieve-guided procedure by an operator with an experience record >10 cases, procedure time was significantly shorter with the Achieve-than with a Lasso-guided approach (118 ± 18 vs. 129 ± 21 min, p < 0.05) as was the duration of fluoroscopy (17 ± 5 vs. 20 ± 7 min, p < 0.05; Fig. 2 ).
Procedural data
The procedure of PVI was completed by cryoballoon alone in 96 cases (94 %). Additional touch-up ablation to a PV using a Freezor Max catheter was required in 6 cases (6 %). Ablation of the cavotricuspid isthmus was performed at the same procedure in 22 cases for documented typical atrial flutter using the technique as we have previously described [15] and balanced across the mapping catheter groups. No other arrhythmia substrate was ablated in any study patient.
A 28-mm cryoballoon was used in 75 cases (74 %), and a 23-mm cryoballoon in 29 cases (28 %). In two cases (2 %), the operator had to change from a 23-mm balloon to a 28-mm balloon or vice versa. AFO was used in 34 and AFA in 68 cases of the 102 procedures with similar clinical characteristics in both groups ( Table 1) . The mean procedure time with the AFA was significantly shorter than with the AFO. The AFA catheter reached nadir temperature significantly faster than the AFO (p < 0.05; Figs. 3 and 4) . The use of AFA was similar in the Achieve and Lasso groups (71 vs. 65 %, p = ns).
Pulmonary vein isolation
A total of 413 PVs were treated in the study patients, and 99 % of identified PVs with PV signals were successful isolated. PV conduction was present at the end of the procedure in only one vein each in two cases, both performed with the Achieve Mapping Catheter and AFO. Acute PV isolation was achieved with cryoballoon alone in 65 cases (96 %) of the Achieve group and in 31 cases (91 %) of the Lasso group (p = ns).
In the Achieve group, the TTI was observed in 62 % of identified PVs with a mean TTI of 47 ± 38 s (range 2-215 s). A significantly shorter TTI was noted in patients treated with AFA than with AFO (34.6 ± 23.4 vs. 43.1 ± 39.1 s, p < 0.01).
The degree of PV occlusion was shown to predict the response to therapy (Fig. 1) . The distinction between grade 4 and grade 5 was significant; therapies associated with grade 5 occlusion gave significantly shorter time to isolation of the vein (40 ± 27 vs. 53 ± 39 s, p < 0.05) and significantly colder nadir temperatures (−53.6 ± 8.6 vs. −50.8 ± 12.5°C, p < 0.05) compared to those associated with a grade 4 occlusion. The PV occlusion degree was similar in the Achieve and Lasso groups. The pressure recorded through the central lumen of the balloon catheter showed a trend toward higher values with occlusions of greater quality but the pressure did not predict the TTI.
Procedure complications
Only one major complication occurred in this study. A patient undergoing Lasso-guided ablation with AFA under general anesthesia developed substantial bleeding into the endotracheal tube during the first cryotherapy to the RSPV. After losing approximately 500 ml of blood in 1 min, the bleeding stopped in response to termination of the freeze with emergency deflation of the balloon, removal of the guide wire from the PV, and reversal of heparin. Emergency bronchoscopy showed no ongoing bleeding, but there was evidence of recent bleeding through the right upper lobe bronchus. The patient made an uncomplicated recovery and was discharged 2 days later; he remained in sinus rhythm during follow-up. There were three other complications in the entire study: two cases of femoral hematoma or pseudoaneurysm requiring thrombin injection and one case of tPNI that continued to the end of the procedure. This phrenic nerve injury was not evident on chest radiography the following day and produced no symptom. The rate of complication was unrelated to assignment (Achieve vs. Lasso), to the model of cryoballoon, or to the size of the balloon ( Table 2) . Two of the three complications happened in cases when general anesthesia was used.
A weakening of diaphragmatic response to phrenic stimulation followed by a full return of function before the end of the procedure was observed in 24 cases (23.5 %). The incidence of this threatened complication was not significantly associated with the assignment to Achieve or Lasso group, the size or model of cryoballoon used, or the mode of anesthesia.
Clinical outcomes
Of 102 participants, 80 cases (78 %) were free from AF at 6 month post ablation. At 12 months, 78 of 98 (79 %) cases who had completed 12-month follow-ups remained AF free . There were no significant differences between the Achieve and Lasso groups in any of these characteristics (a) Fig. 3 Comparison of equipment for procedure and fluoroscopy duration. The graphs show that procedure duration and fluoroscopic duration are significantly shorter in the Achieve group by subgroup analysis; the differences are not shown in the whole study population between mapping catheter groups but are found significant between cryoballoon groups with or without antiarrhythmic drugs. The clinical outcome was not associated with the Achieve or Lasso mapping catheter used but associated with the cryoballoon model (87 vs. 62 %, p = 0.004, at 6 months; 88 vs. 61 %, p = 0.002, at 12 months for AFA vs. AFO). No association was noted between clinical outcome and the cryoballoon size, or the mode of anesthesia.
Discussion
Our study has shown a significant reduction in procedure time and fluoroscopy duration with the Achieve Mapping Catheter that happens after operators gained a great deal of experience in its use; such advantage was not demonstrated when operators were still in the early stage of the learning curve. This study has confirmed the findings from other reports that the use of the second-generation cryoballoon significantly shortens procedure time and is associated with better clinical outcomes.
Procedure efficiency
The Achieve catheter, which is deployed through the Arctic Front guide wire lumen, could minimize the number of catheter exchanges and hence of shorten procedure time. However, the expected efficiency gain was not demonstrated in this study while it included the cases of Achieveguided procedure performed by operators with limited experience. Subgroup analysis eliminates the confounder and proves the advantage of the novel catheter. Our findings are not fully consistent with that reported in early studies [4] ; however, operator information was not available in the most previous non-randomized studies on the Achieve [9, 10, 16, 17] . People who practice in this area would agree that operator dexterity is a significant confounding factor; it can affect study findings. Our results demonstrate that there is a learning curve before an operator reaches full efficiency with the Achieve catheter. Our findings are consistent with those from other published studies [8] [9] [10] regarding the AFA, which allows the freezing time to be reduced while attaining similar or better rates of PVI. This improvement of efficiency attributes mainly to the features of the new cryoballoon but not correlated with the type of mapping catheter used.
Procedure safety
Achieve catheter allows the procedure to be performed using a single transseptal puncture. One may expect a better safety record of procedures for this reason; however, there are multiple factors which could affect the overall rate of procedure complications. This study confirms that cryoablation is a safe method of achieving PVI, with a rate of serious complication of less than 1 % in our series.
Our results demonstrate that a single transseptal puncture and single-balloon strategy is almost always practical, efficient, and safe even without preselection for anatomic suitability based on any pre-procedure imaging of PV for cryoballoon therapy. In the Straube et al. study, CT/MRI were used to determine PV anatomy [10] . Straube et al. used 23-plus 28-mm cryoballoons in 21 % of the study patients [10] . Other investigators reported using both balloons in as many as 47.7 % of cases [18] . This study has proven a single-balloon strategy is fiscally more achievable.
Other studies reported that AFA was associated to a greater incidence of PNP when compared with AFO. This was not observed in our study regarding the association between the incident of PNP or tPNW and AFA. The use of Achieve did not increase or decrease the advert events. Close monitoring was constantly applied during ablating the right PVs, and the freezing would be terminated if the temperature dropped below −65°C. Great incidence of PNP can be reduced with such strategy. 
Procedure efficacy
The Achieve catheter may provide real-time PV signals during PVI procedures using an Arctic Front cryoballoon, allowing real-time verification of PVI during delivery of cryotherapy. Potentially, real-time verification of PVI could guide cryotherapy and improve procedure efficacy and efficiency by allowing the operator to titrate the dose of cryotherapy according to effect. We did not use the data derived from the Achieve in this way. In previous research populations, the Achieve has registered electrograms of sufficient quality to determine TTI in 31-76 % [4, 10, 19, 20] of PVs. Failure to register clear electrograms during therapy may occur due to an absence of excitable tissue in the vein wall or because the shape of the vein requires that the Achieve catheter is placed in a distal position to attain sufficient stability to support the balloon. We have tried to minimize this effect by using a larger balloon size in 75 % of cases to place the balloon and therefore the Achieve Mapping Catheter as proximally as possible in the vein. When electrograms could not be observed during cryotherapy, the Achieve Mapping Catheter can be used to determine the presence or absence of electrograms in the proximal part of the vein or in the antrum of the vein before and after therapy in the same way as a Lasso-type catheter.
Chierchia et al. observed real-time PVI in 55 % of cases [4] , and Kuhne et al. reported seeing real-time isolation in 50 % [19] . Furnkranz et al. [20] found it in 49 % of targeted PVs using AFO and 76 % using AFA. No such difference was observed in our study or by Straube et al. (31 vs. 44 %) [10] between AFO and AFA suggesting that the effect described by Furnkanz et al. may represent an order effect with improvement in their utilization of the Achieve Mapping Catheter as they gained experience with it.
The second-generation cryoballoon is designed to provide a more contiguous lesion by delivering cryotherapy more uniformly with the expectation of improved procedural efficacy and clinical outcome compared to the first-generation cryoballoon. The improved efficacy has been demonstrated by a number of clinical studies [8, 20] . Consistent with previous literature, our study shows a 99 % of acute PVI and improved clinical outcome. Again, this is not related to either Achieve or Lasso catheter.
Study limitations
This study was conducted in a single center by operators already experienced in the use of the Arctic Front and of Lassostyle catheters but initially without experience in the use of the Achieve Mapping Catheter. This lack of experience may have reduced our ability to detect the advantages of the Achieve in the whole study population. The introduction of the AFA during the recruitment complicated the data analysis and interpretation.
The approach of comparing catheters in an open-label manner might raise a potential bias if operators started with a preferred concept. In a study of methods as dissimilar as the Achieve Mapping Catheter and the Lasso, there was no alternative to an open-label design. We have tried to minimize any effect of bias by using multiple operators, most of whom had no conflict of interest and all of whom had an interest in minimizing procedure duration for ethical and practical reasons.
We may have underestimated the potential benefits of the Achieve Mapping Catheter because of the limited utilization of the information derived from it in the current study. Our rigid protocol did not permit the operator to adjust the duration of cryotherapy according to TTI. This limitation was inevitable because no information on the correlation between TTI and long-term outcome was available at the time the study was designed. It remains to be determined whether the tailoring of therapy based on TTI information from the Achieve Mapping Catheter can improve the efficacy and efficiency of ablation procedures.
Study implications and future work
The findings of this randomized trial support that it is more efficient to use the Achieve catheter in conjunction with the newer cryoballoon in PVI. This study indicates operators have to pass a significant learning curve in performing the procedure before benefiting from the device. There has no universal consensus on the optimal duration of cryotherapy delivery; further investigation on how the visible TTI may guide the therapy is warranted aiming to shorten the procedure time without compromising the efficacy and clinical outcome. The grading system for pulmonary vein occlusion that we designed for this trial was potentially a predictor of TTI. It requires further verification to determine its role in PVI.
Conclusion
The use of the Achieve Mapping Catheter can reduce procedure and fluoroscopic durations compared to established catheters used for pulmonary vein mapping in cryoballoon ablation for PAF, only after operators gained sufficient experience. The type of circular mapping catheter used does not affect the procedure efficiency and safety demonstrated by the second-generation cryoballoon, which has improved overall procedure efficiency of cryoballoon ablation in PAF without compromising safety compared with the first-generation cryoballoon.
